1-{2-[(5-methyl-furan-2-ylmethyl)-amino]-quinolin-6-yl}-3-(1-methyl-piperidin-4-yl)-urea | 1187529-89-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-{2-[(5-methyl-furan-2-ylmethyl)-amino]-quinolin-6-yl}-3-(1-methyl-piperidin-4-yl)-urea
• 英文别名: 1-[2-[(5-Methylfuran-2-yl)methylamino]quinolin-6-yl]-3-(1-methylpiperidin-4-yl)urea
• CAS: 1187529-89-0
• 化学式: C₂₂H₂₇N₅O₂
• 分子量: 393.489
• InChiKey: YSASFJQJPOWBJS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  82.4
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• 2-AMINOQUINOLINES
  申请人：Kolczewski Sabine

  公开号：US20090233927A1

  公开（公告）日：2009-09-17

  The present invention is concerned with 2-aminoquinoline derivatives of formula I wherein R 1 and R 2 are as described herein and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them, and methods for their manufacture. These compounds are 5-HT 5A receptor antagonists, useful for the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, dementia, disorders of eating behaviors, sexual dysfunction, sleep disorders, abuse of drugs, motor disorders such as Parkinson's disease, psychiatric disorders or gastrointestinal disorders.

  本发明涉及式I的2-氨基喹啉衍生物，其中R1和R2如此描述，并且其药学上可接受的盐，包含它们的制药组合物以及其制造方法。这些化合物是5-HT5A受体拮抗剂，可用于预防和/或治疗抑郁症、焦虑症、精神分裂症、惊恐障碍、广场恐惧症、社交恐惧症、强迫症、创伤后应激障碍、疼痛、记忆障碍、痴呆、饮食行为障碍、性功能障碍、睡眠障碍、药物滥用、帕金森病等运动障碍、精神障碍或胃肠障碍的治疗。
• 2-AMINOQUINOLINES AS 5-HT5A RECEPTOR ANTAGONISTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2254666A1

  公开（公告）日：2010-12-01
• US8350028B2
  申请人：——

  公开号：US8350028B2

  公开（公告）日：2013-01-08
• [EN] 2-AMINOQUINOLINES AS 5-HT5A RECEPTOR ANTAGONISTS<br/>[FR] 2-AMINOQUINOLÉINES EN TANT QU'ANTAGONISTES DES RÉCEPTEURS 5-HT5A
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009112395A1

  公开（公告）日：2009-09-17

  The present invention is concerned with 2-Aminoquinoline derivatives as 5-HT5A receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful in the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, dementia, disorders of eating behaviors, sexual dysfunction, sleep disorders, abuse of drugs, motor disorders such as Parkinson's disease, psychiatric disorders or gastrointestinal disorders. In particular, the present invention is concerned with compounds of the general formula (I) wherein R and R are as described herein.